Redeye views the recent news from Lifecare, which confirms a minimum operational longevity of six mo...
• NOI increased 28% y-o-y, +6% vs. ABGSCe • Value changes -1.
Atria reported Q2 EBIT of EUR 10m, 17% (EUR 2.1m) below Refinitiv consensus.
Redeye retains its positive view on ADDvise following a Q2 report with numbers aligning with the pre...
• Net sales -13% vs. ABGSCe, adj. EBITA -13% vs ABGSCe • We lower '23e-'25e adj.
Redeye is positive to Arise’s Q2 report as it beat our estimates and provided an attractive outlook ...
Redeye believes the Q1 report from Lagercrantz was strong, especially from a profit perspective, and...
Redeye retains its positive view despite lowering its Base Case and forecasts.
Ökade intäkter med operativa verksamheter som drivare Intäkterna under Q2’23 uppgick till 109,6 mkr ...
Solid Q2’23 - Skaftåsen är återigen vinstavräknad Arise rapporterade en solid Q2’23.
Redeye retains its positive view on Lagercrantz following a Q1 report with 6% organic growth and str...
• Net sales SEK 170m, -13% vs. ABGSCe, -9% vs. Factset cons • Adj.
Redeye sees a mixed Q2 report from Vertiseit, with strong q/q ARR growth, while OPEX and cash flow w...
• UK continues to support the group • Rebalancing expectations lead to -3% on '23e estimates • We lo...
Redeye gives a short comment on yesterday’s announcement of a CEO change in Xavi Solutions, which so...
Q-linea is in a transition period after the break with Thermo Fisher and in Q2 there are two deliver...
Redeye provides an update in relation to Enzymatica’s Q2 2023 report.
Cibus' Q2 2023 income from property management (IFPM) was in line with our expectations but slightly...
• Q2 results due on 15 August • Expected to maintain stable organic growth of 5% • We also forecast ...
Kvartalet i korthet: Omsättningen uppgick till 8,8 mkr (9,6) och rörelseresultatet uppgick till -11,...
